James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.
James N. Gerson, MD
Advertisement
Articles by James N. Gerson, MD
James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.
James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.
James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.
James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, discusses strategies aimed at alleviating toxicity in older patients with mantle cell lymphoma (MCL).
James N. Gerson, MD, discusses the watch-and-wait approach for patients with mantle cell lymphoma.
James N. Gerson, MD, discusses the phase III CLL14 trial evaluating the combination of venetoclax and obinutuzumab versus chlorambucil and obinutuzumab as frontline therapy in chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLLPublished: October 4th 2019 | Updated:
Dr. Gerson on the Watch-and-Wait Approach in MCLPublished: October 7th 2019 | Updated:
Dr. Gerson on Strategies Aimed at Alleviating Toxicity in Older Patients With MCLPublished: October 15th 2019 | Updated:
Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLLPublished: October 16th 2019 | Updated:
Dr. Gerson on Updates in Relapsed/Refractory MCLPublished: December 6th 2019 | Updated:
- Dr. Gerson on Clinical Trial Accrual in MCL
Published: May 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5